SCI时时刷

search
+
Alternating chemotherapy with VDC-IE as effective first-line treatment in a patient with SMARCA4-deficient undifferentiated tumor
Alternating chemotherapy with VDC-IE as effective first-line treatment in a patient with SMARCA4-deficient undifferentiated tumor
SMARCA4-deficient undifferentiated tumor (SMARCA4-UTs) is an extremely rare and aggressive entity where no consensus on sy...
American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia
American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia
In recent years, there has been massive advances in the treatment of chronic lymphocytic leukemia (CLL) from chemoimmunoth...
Prediction of epidermal growth factor receptor mutation status by textural features in stage IV lung adenocarcinoma
Prediction of epidermal growth factor receptor mutation status by textural features in stage IV lung adenocarcinoma
The purpose of this study was to assess the correlation between textural features from 18fluorodeoxyglucose positron emiss...
Seminal vesicle metastasis from transverse colon adenocarcinoma: a unique case report
Seminal vesicle metastasis from transverse colon adenocarcinoma: a unique case report
Seminal vesicle metastasis from colon adenocarcinoma is very rare, with only two case reports in the literature. Also, pos...
β-adrenergic modulation of IL-6/gp130 and SOCS-1 in multiple myeloma: therapeutic strategy for stress induced-inflammatory response
β-adrenergic modulation of IL-6/gp130 and SOCS-1 in multiple myeloma: therapeutic strategy for stress induced-inflammatory response
Multiple Myeloma (MM) is considered an incurable, biologically heterogeneous disease of the plasma cells. The clinical dat...
Innovative therapeutic concepts for biliary tumors
Innovative therapeutic concepts for biliary tumors
In recent years there have been significant changes in the treatment of bile duct carcinoma. Immunotherapy has been includ...
Acute myeloid leukemia patient with active disseminated tuberculosis bridged to transplant with reduced 14-day venetoclax and azacitidine schedule
Acute myeloid leukemia patient with active disseminated tuberculosis bridged to transplant with reduced 14-day venetoclax and azacitidine schedule
A 59-year-old female patient was diagnosed with acute myeloid leukemia and tuberculosis. As a further co...
(Neo)adjuvant approaches in lung cancer—paving the road to a cure
(Neo)adjuvant approaches in lung cancer—paving the road to a cure
Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of metastatic non-small-cell lung cancer (N...
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
Metastatic hormone-sensitive prostate cancer (mHSPC) displays both simultaneous and sequential patterns of metastasis, emp...
Total neoadjuvant therapy for each locally advanced rectal cancer?
Total neoadjuvant therapy for each locally advanced rectal cancer?
The treatment paradigm for locally advanced rectal cancer has changed in recent years. Neoadjuvant radiochemotherapy follo...
Pulmonary puzzles: salivary gland-type tumors of the lung and their metastatic equivalents
Pulmonary puzzles: salivary gland-type tumors of the lung and their metastatic equivalents
In the last decade, the understanding of lung neoplasms, particularly rare salivary gland-type tumors (SGT), has deepened ...
Transformation of epidermal growth factor receptor-mutated non-small cell lung cancer into small cell lung cancer—case report
Transformation of epidermal growth factor receptor-mutated non-small cell lung cancer into small cell lung cancer—case report
Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) generally has a favorable prog...
Molecular typing—new targets and therapy options for upper GI carcinomas with a focus on adenocarcinomas of the esophagus, gastroesophageal junction, and stomach
Molecular typing—new targets and therapy options for upper GI carcinomas with a focus on adenocarcinomas of the esophagus, gastroesophageal junction, and stomach
The biomarker developments in adenocarcinomas of the esophagus, gastroesophageal junction, and stomach are currently very ...
Metastasis-directed therapy: new standard or too early to change paradigm?
Metastasis-directed therapy: new standard or too early to change paradigm?
Metastasis-directed therapy (MDT) is an emerging treatment strategy for patients with oligometastatic prostate cancer (PCa...
Upper-GI highlights from ASCO and ASCO-GI 2023 meetings: changing paradigm in treatment sequence
Upper-GI highlights from ASCO and ASCO-GI 2023 meetings: changing paradigm in treatment sequence
The annual meeting of the American Society of Medical Oncology (ASCO) was held as usual in Chicago, while the meeting focu...
Total neoadjuvant therapy for each local advanced rectal cancer?
Total neoadjuvant therapy for each local advanced rectal cancer?
The treatment paradigm for locally advanced rectal cancer has changed in recent years. Neoadjuvant radiochemotherapy follo...
Management of oligometastatic prostate cancer
Management of oligometastatic prostate cancer
This study aimed to review the current management strategies for oligometastatic prostate cancer (omPCa), focusing on thei...
Diagnosis and management of mediastinal extragonadal germ cell tumors
Diagnosis and management of mediastinal extragonadal germ cell tumors
Extragonadal germ cell tumors (EGCT) are rare and comprise only 2–3% of all testicular germ cell tumors. The majorit...
(Neo)adjuvant approaches: pavement on the road to cure—breast cancer
(Neo)adjuvant approaches: pavement on the road to cure—breast cancer
During the past few decades, major advances have been achieved in the treatment of early breast cancer (BC) resulting in i...
A GLOBAL CONGRESS DIGEST ON CHRONIC LYMPHOCYTIC LEUKEMIA. Report from International Workshop on Chronic Lymphocytic Leukemia (XX iwCLL 2023), 6th–9th October, 2023, Boston, USA
A GLOBAL CONGRESS DIGEST ON CHRONIC LYMPHOCYTIC LEUKEMIA. Report from International Workshop on Chronic Lymphocytic Leukemia (XX iwCLL 2023), 6th–9th October, 2023, Boston, USA
Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a sh...
A GLOBAL CONGRESS DIGEST ON LUNG CANCER. Report from the ESMO Hybrid Congress , 20th – 24th October 2023, Madrid, Spain
A GLOBAL CONGRESS DIGEST ON LUNG CANCER. Report from the ESMO Hybrid Congress , 20th – 24th October 2023, Madrid, Spain
Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a sh...
ASCO 2023: highlights in breast cancer
ASCO 2023: highlights in breast cancer
The 2023 annual meeting of the American Society of Clinical Oncology (ASCO) was again held in June 2023 in Chicag...
Cancer of unknown primary—state of the art
Cancer of unknown primary—state of the art
The Cancer of Unknown Primary (CUP) syndrome does not represent a single clinical entity but comprises a diverse group of ...
Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023
Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023
Implementation of targeted drugs in the treatment landscape of indolent B‑cell malignancies has facilitated long-ter...
Supportive management
Supportive management
The introduction of checkpoint inhibitor therapy and advances in targeted therapy...
Prostate cancer special—part 1
Prostate cancer special—part 1
Conflict of interest S.F. Shariat declares the following competing interes...
HER2 in focus—gastric cancer
HER2 in focus—gastric cancer
Conflict of interest A. Ilhan-Mutlu: Participation in advisory boards orga...
ASCO 2023—partnering with patients: the cornerstone of cancer care and research
ASCO 2023—partnering with patients: the cornerstone of cancer care and research
For the 2023 annual meeting of the American Society of Clinical Oncology (ASC...
WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients
WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients
The Wnt pathway is aberrantly activated in chronic lymphocytic leukemia (CLL) and contributes to the antiapoptotic and mit...
A CONGRESS DIGEST ON RADIOLABELED THERANOSTICS FOR SOLID TUMORS. Report from the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), September 9th – 13th, 2023, Vienna
A CONGRESS DIGEST ON RADIOLABELED THERANOSTICS FOR SOLID TUMORS. Report from the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), September 9th – 13th, 2023, Vienna
Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a sh...
阅读更多
format_indent_increase